A guide towards pre-pregnancy management of defective implantation and placentation

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 25, Issue 3, 2011, Pages 367-387

  Urato, Adam C ^a   Norwitz, Errol R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

implantation; placenta; placentation; pre eclampsia; uterine artery Doppler

Indexed keywords

ACETYLSALICYLIC ACID; ADAM PROTEIN 12; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DISINTEGRIN; ENDOGLIN; FISH OIL; HEPARIN; METALLOPROTEINASE; NITRIC OXIDE; PLACENTA PROTEIN; PLACENTAL PROTEIN 13; PROSTAGLANDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VITAMIN D;

ANTICOAGULANT THERAPY; CELL INVASION; DIET SUPPLEMENTATION; DOPPLER FLOWMETRY; HUMAN; MATERNAL BLOOD; MATERNAL SERUM; NONHUMAN; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREPREGNANCY CARE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SCREENING TEST; SECONDARY PREVENTION; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; TROPHOBLAST; UTERINE ARTERY; VAGINA BLEEDING;

EMBRYO IMPLANTATION; FEMALE; HUMANS; PLACENTA DISEASES; PLACENTATION; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 79955796083     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2011.01.003     Document Type: Review

References (161)

1. Zinaman MJ, Clegg ED, Brown CC et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65: 503-509. (Pubitemid 26069103)
2. Hoozemans DA, Schats R, Lambalk CB et al. Human embryo implantation: current knowledge and clinical implications in assisted reproductive technology. Reprod BioMed Online 2004; 9: 692-715. (Pubitemid 40028888)
3. Wilcox AJ, Weinberg CR, O'Connor JF et al. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189-194.
4. Pijnenborg R, Robertson WB, Brosens I et al. Trophoblast invasion and the establishment of haemochorial placentation in man and laboratory animals. Placenta 1981; 2: 71-91. (Pubitemid 11179363)
5. Enders AC & Lopata A. Implantation in the marmoset monkey: expansion of the early implantation site. Anat Rec 1999; 256: 279-299. (Pubitemid 29506279)
6. Benirschke K & Kaufmann P. Early development of the human placenta. In Benirschke K & Kaufmann P (eds.). Pathology of the human placenta. New York: Springer-Verlag, 1991, pp. 13-21.
7. Pijnenborg R, Bland JM, Robertson WB et al. The pattern of interstitial trophoblastic invasion of the myometrium in early human pregnancy. Placenta 1981; 2: 303-316. (Pubitemid 11022999)
8. Brosens IA. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 1977; 4: 573-593. (Pubitemid 8234457)
9. Meekins JW, Pijnenborg R, Hanssens M et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669-674. (Pubitemid 24251519)
10. Zhou Y, Damsky CH & Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99: 2152-2164.
11. Redman CW & Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-1594. (Pubitemid 40807500)
12. Roberts JM, Taylor RN, Musci TJ et al. Preeclampsia: an endothelial cell disorder.AmJ Obstet Gynecol 1989; 161: 1200-1204.
13. Kim YM, Bujold E, Chaiworapongsa T et al. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003; 189: 1063-1069. (Pubitemid 37373899)
14. Ozturk O, Bhattacharya S, Saridogan E et al. Role of utero-ovarian vascular impedance: predictor of ongoing pregnancy in an IVF-embryo transfer programme. Reprod BioMed Online 2004; 9: 299-305. (Pubitemid 39214168)
15. Jauniaux E. Design, beauty and differentiation: the human fetus during the first trimester of gestation. Reprod BioMed Online 2000; 1: 107-108.
16. Norwitz ER, Schust DJ & Fisher SJ. Implantation and the survival of early pregnancy. N Engl J Med 2001; 345: 1400-1408.
17. Maathuis JB & Kelly RW. Concentrations of prostaglandins F2alpha and E2 in the endometrium throughout the human menstrual cycle, after the administration of clomiphene or an oestrogen-progestogen pill and in early pregnancy. J Endocrinol 1978; 77: 361-371. (Pubitemid 8354929)
18. Abel MH, Smith SK & Baird DT. Suppression of concentration of endometrial prostaglandin in early intra-uterine and ectopic pregnancy in women. J Endocrinol 1980; 85: 379-386. (Pubitemid 10063166)
19. Norwitz ER & Wilson T. Secretory component: a potential regulator of endometrium/decidual prostaglandin production in early human pregnancy. Am J Obstet Gynecol 2000; 183: 108-117. (Pubitemid 30626036)
20. Jaschevatzky OE, Shalit A, Grunstein S et al. Increased decidual prostaglandin E concentration in human abortion. Br J Obstet Gynaecol 1983; 90: 958-960. (Pubitemid 13007775)
21. Peyron R, Aubeny E, Targosz V et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328: 1509-1513. (Pubitemid 23147779)
22. Csapo AI & Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Lutectomy evidence. Obstet Gynecol Surv 1978; 33: 69-81. (Pubitemid 8267883)
23. Schust DJ, Anderson DJ & Hill JA. Progesterone-induced immunosuppression is not mediated through the progesterone receptor. Hum Reprod 1996; 11: 980-985. (Pubitemid 26177265)
24. Wilson T, Liggins GC, Aimer GP et al. The effect of progesterone on the release of arachidonic acid from human endometrial cells stimulated by histamine. Prostaglandins 1986; 31: 343-360. (Pubitemid 16168188)
25. Norwitz ER, Bhandari V, Wright JR, et al. Surfactant protein-A (SP-A) selectively inhibits prostaglandin F2a (PGF2a) production by term decidual stromal cells: The fetus controls the timing of labor. J Clin Endocrinol Metab (in press).
26. Wilson T, Liggins GC & Joe L. Purification and characterization of a uterine phospholipase inhibitor that loses activity after labor onset in women. Am J Obstet Gynecol 1989; 160: 602-606. (Pubitemid 19092142)
27. Wilson T & Christie DL. Gravidin, an endogenous inhibitor of phospholipase A2 activity is secretory component of IgA. Biochem Biophys Res Commun 1991; 176: 447-452.
28. Wilson T, Liggins GC, Aimer GP et al. Partial purification and characterization of two compounds from amniotic fluid which inhibits phospholipase activity in human endometrial cells. Biochem Biophys Res Commun 1985; 131: 22-29. (Pubitemid 16251113)
29. Wu YZ, Manevich Y, Baldwin JL et al. Interaction of surfactant protein A with peroxiredoxin 6 regulates phospholipase A2 activity. J Biol Chem 2006; 281: 7515-7525. (Pubitemid 43847522)
30. Salafia CM, Lopez-Zeno JA, Sherer DM et al. Histologic evidence of old intrauterine bleeding is more frequent in prematurity. Am J Obstet Gynecol 1995; 173: 1065-1070.
31. Aoyama K, Suzuki Y, Sato T et al. Cardiac failure caused by severe pre-eclampsia with placental abruption, and its treatment with anti-hypertensive drugs. J Obstet Gynaecol Res 2003; 29: 339-342. (Pubitemid 37455388)
32. Nagy S, Bush M, Stone J et al. Clinical significance of subchorionic and retroplacental hematomas detected in the first trimester of pregnancy. Obstet Gynecol 2003; 102: 94-100. (Pubitemid 36792129)
33. Weiss JL, Malone FD, Vidaver J, et al. For the FASTER Consortium. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004; 190: 745-750. (Pubitemid 38406787)
34. Alfirevic Z, Roberts D & Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? a systematic review. Euro J Obstet Gynecol Reprod Biol 2002; 101: 6-14. (Pubitemid 34142238)
35. Dudding TE & Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemostasis 2004; 91: 700-711. (Pubitemid 38477450)
36. Lin J & August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005; 105: 182-192. (Pubitemid 40189930)
37. Branch DW, Porter TF, Rittenhouse L, et al. For the national institute of child health and human development maternal-fetal medicine units network. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 2001; 184: 825-832.
38. Lockwood CJ, Nemerson Y, Guller S et al. Progestational regulation of human endometrial stromal cell tissue factor expression during decidualization. J Clin Endocrinol Metab 1993; 76: 231-236. (Pubitemid 23027585)
39. Lockwood CJ, Krikun G, Papp C et al. The role of progestationally regulated stromal cell tissue factor and type-1 plasminogen activator inhibitor (PAI-1) in endometrial hemostasis and menstruation. Ann NY Acad Sci 1994; 734: 57-79.
40. Lockwood CJ, Paidas M, Krikun G et al. Inflammatory cytokine and thrombin regulation of interleukin-8 and intercellular adhesion molecule-1 expression in first trimester human decidua. J Clin Endocrinol Metab 2005; 90: 4710-4715. (Pubitemid 41159362)
41. Colotta F, Sciacca FL, Sironi M et al. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994; 144: 975-985. (Pubitemid 24160638)
42. Grandaliano G, Valente AJ & Abboud HE. A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production. J Exp Med 1994; 179: 1737-1741. (Pubitemid 24129596)
43. Burri PH, Hlushchuk R & Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dynamics 2004; 231: 474-488. (Pubitemid 39410882)
44. Clark DE, Smith SK, He Y et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-1548. (Pubitemid 28549874)
45. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658. (Pubitemid 36278583)
46. Tsatsaris V, Goffin F, Munaut C et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-5563. (Pubitemid 37452769)
47. Buhimschi CS, Norwitz ER, Funai E et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005; 192: 734-741. (Pubitemid 40311263)
48. Lockwood CJ, Krikun G, Toti P et al. Thrombin regulates expression of soluble fms-like tyrosine kinase-1 (sFlt-1) in first trimester decidual cells: implications for preeclampsia. Am J Pathol 2007; 170: 1398-1405. (Pubitemid 47339346)
49. Conde-Agudelo A, Villar J & Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104: 1367-1391. (Pubitemid 40458737)
50. Olofsson P, Laurini RN & Marsal K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 1993; 49: 161-168. (Pubitemid 23220935)
51. Cnossen JS, Morris RK, ter Riet G et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178: 701-711.
52. Rana S, Karumanchi SA & Norwitz ER. Screening for hypertensive disorders of pregnancy. In Haezell A, Norwitz ER, Kenny LC & Baker PN (eds.). Hypertension in pregnancy. Cambridge, UK: Cambridge University Press, 2010, pp. 45-61.
53. Toal M, Chan C, Fallah S et al. Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol 2007; 196: 363.e1-363.e7.
54. Toal M, Keating S & Machin G. Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images. Am J Obstet Gynecol 2008; 198: 330.e1-330.e7.
55. Viero S, Chaddha V, Alkazaleh F et al. Prognostic value of placental ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries. Placenta 2004; 25: 735-741. (Pubitemid 39185951)
56. Pretorius DH, Nelson TR, Baergen RN et al. Imaging of placental vasculature using three-dimensional ultrasound and color power Doppler: a preliminary study. Ultrasound Obstet Gynecol 1998; 12: 45-49. (Pubitemid 28379290)
57. Konje JC, Huppertz B, Bell SC et al. 3-dimensional colour power angiography for staging human placental development. Lancet 2003; 362: 1199-1201. (Pubitemid 37255347)
58. Hafner E, Metzenbauer M, Höfinger D et al. Comparison between three-dimensional placental volume at 12 weeks and uterine artery impedance/notching at 22 weeks in screening for pregnancy-induced hypertension, pre-eclampsia and fetal growth restriction in a low-risk population. Ultrasound Obstet Gynecol 2006; 27: 652-657. (Pubitemid 43967368)
59. Morris RK, Cnossen JS, Langejans M et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 2008; 4: 8-33.
60. Than NG, Pick E, Bellyei S et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem 2004; 271: 1065-1078. (Pubitemid 38373040)
61. Nicolaides KH, Bindra R, Turan OM et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006; 27: 13-17. (Pubitemid 43129084)
62. Chafetz I, Kuhnreich I, Sammar M et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197: 35.e1-35.e7.
63. Romero R, Kusanovic JP, Than NG et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008; 199: 122.e1-122.e11.
64. Huppertz B, Sammar M, Chefetz I et al. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008; 24: 230-236.
65. Khalil A, Cowans NJ, Spencer K et al. First trimester maternal serum placental protein 13 for the prediction of preeclampsia in women with a priori high risk. Prenat Diagn 2009; 29: 781-789.
66. Gonen R, Shahar R, Grimpel YI et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008; 115: 1465-1472.
67. Cowans NJ, Spencer K & Meiri H. First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes. Prenat Diagn 2008; 28: 121-125. (Pubitemid 351311153)
68. Cowans NJ, Stamatopoulou A, Matwejew E et al. First-trimester placental growth factor as a marker for hypertensive disorders and SGA. Prenat Diagn 2010; 30: 565-570.
69. Akolekar R, Syngelaki A, Beta J et al. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn 2009; 29: 1103-1108.
70. Koga K, Osuga Y, Yoshino O et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348-2351. (Pubitemid 36549917)
71. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683. (Pubitemid 38364626)
72. McKeeman GC, Ardill JE, Caldwell CM et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240-1246. (Pubitemid 39421577)
73. Ahmad S & Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95: 884-891. (Pubitemid 39435003)
74. Hertig A, Berkane N, Lefevre G et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004; 50: 1702-1703. (Pubitemid 39121252)
75. Chaiworapongsa T, Romero R, Kim YM et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18. (Pubitemid 40515938)
76. Wathen KA, Tuutti E, Stenman UH et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006; 91: 180-184. (Pubitemid 43069135)
77. Rana S, Karumanchi SA, Levine RJ et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-142. (Pubitemid 46986022)
78. Vatten LJ, Eskild A, Nilsen TI et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196: 239.e1-239.e6.
79. Widmer M, Villar J, Benigni A et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007; 109: 168-180. (Pubitemid 46035522)
80. Audibert F, Boucoiran I, An N et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010; 203: 383.e1-383.e8.
81. Poon LC, Chelemen T, Granvillano O et al. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008; 112: 1082-1090.
82. Wallukat G, Homuth V, Fischer T et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945-952. (Pubitemid 29169601)
83. Xia Y, Wen H, Bobst S et al. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003; 10: 82-93. (Pubitemid 36184763)
84. Zhou CC, Zhang Y, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14: 855-862.
85. Fu ML, Herlitz H, Schulze W et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000; 18: 945-953. (Pubitemid 30459497)
86. Karumanchi SA & Lindheimer MD. Preeclampsia pathogenesis: "triple a rating"-autoantibodies and antiangiogenic factors. Hypertension 2008; 51: 991-992.
87. Speer PD, Powers RW, Frank MP et al. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol 2008; 198: 112.e1-112.e7.
88. Savvidou MD, Hingorani AD, Tsikas D et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361: 1511-1517. (Pubitemid 36566342)
89. Goodlin RC, Haesslein HO & Fleming J. Aspirin for the treatment of recurrent toxemia [letter]. Lancet 1978; 2: 51. (Pubitemid 9043018)
90. Imperiale TF & Petrulis AS. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA 1991; 266: 261-264.
91. Italian study of aspirin in pregnancy. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Lancet 1993; 341: 396-400.
92. Caritis S, Sibai B, Hauth J et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National institute of child health and human development network of maternal-fetal medicine units. N Engl J Med 1998; 338: 701-705.
93. CLASP. A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343: 619-629.
94. Coomarasamy A, Honest H, Papaioannou S et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101: 1319-1332. (Pubitemid 36694362)
95. Duley L, Henderson-Smart DJ, Knight M et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2004; 2. CD004659.
96. Askie LM, Duley L, Henderson-Smart DJ et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-1798. (Pubitemid 46782996)
97. Subtil D, Goeusse P, Puech F et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 1). BJOG 2003; 110: 475-484.
98. Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414.
99. Norwitz ER, Robinson JN & Repke JT. Prevention of preeclampsia: is it possible? Clin Obstet Gynecol 1999; 42: 436-454.
100. Belizan JM, Villar J & Repke JT. The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence. Am J Obstet Gynecol 1988; 158: 898-902.
101. Bucher H, Guyatt GH, Cook RJ et al. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA 1996; 275: 1113-1117.
102. Lindheimer MD, Taler SJ & Cunningham FG. Hypertension in pregnancy. J Am Soc Hypertens 2010; 4: 68-78.
103. Hofmeyr GJ, Duley L & Atallah A. Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG 2007; 114: 933-943. (Pubitemid 47052743)
104. Trumbo PR & Ellwood KC. Supplemental calcium and risk reduction of hypertension, pregnancy-induced hypertension, and preeclampsia: an evidence-based review by the US Food and Drug Administration. Nutr Rev 2007; 65: 78-87. (Pubitemid 351804382)
105. American College of Obstetrician and Gynecologists. Antiphospholipid syndrome. ACOG Practice Bulletin #68. Obstet Gynecol 2011; 117: 192-199.
106. Scifres CM & Macones GA. The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction? Am J Obstet Gynecol 2008; 199: 344.e1-344.e7.
107. American College of Obstetrician and Gynecologists. Inherited thrombophilias in pregnancy. ACOG Practice Bulletin number 113. Obstet Gynecol 2010; 116: 212-222.
108. Conrad KP & Vernier KA. Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats. Am J Physiol 1989; 257: 847-853.
109. Meher S & Duley L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2. CD006490.
110. Geleijnse JM, Giltay EJ, Grobbee DE et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493-1499. (Pubitemid 34921171)
111. Makrides M, Duley L & Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev 2006; 3. CD003402.
112. Mikhail MS, Anyaegbunam A, Garfinkel D et al. Preeclampsia and antioxidant nutrients: decreased plasma levels of reduced ascorbic acid, alpha-tocopherol, and beta-carotene in women with preeclampsia. Am J Obstet Gynecol 1994; 171: 150-157. (Pubitemid 24254434)
113. Poston L, Briley AL, Seed PT et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367: 1145-1154.
114. Spinnato 2nd JA, Freire S, Pinto E et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol 2007; 110: 1311-1318. (Pubitemid 351326075)
115. Villar J, Purwar M, Merialdi M, et al. For the WHO Vitamin C and Vitamin E trial group. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for preeclampsia in populations of low nutritional status from developing countries. BJOG 2009; 116: 780-788.
116. Roberts JM, Myatt L, Spong CY et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362: 1282-1291.
117. De Snoo K. The prevention of eclampsia. Am J Obstet Gynecol 1937; 34: 911-939.
118. Duley L, Henderson-Smart D & Meher S. Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev 2005; 4. CD005548.
119. Churchill D, Beevers GD, Meher S et al. Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev 2007; 1. CD004451.
120. Abalos E, Duley L, Steyn DWet al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007; 1. CD002252.
121. Bodnar LM, Catov JM, Simhan HN et al. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab 2007; 92: 3517-3522. (Pubitemid 47435329)
122. Robinson CJ, Alanis MC, Wagner CL et al. Plasma 25-hydroxyvitamin D levels in early-onset severe preeclampsia. Am J Obstet Gynecol 2010; 203: 366.e1-366.e6.
123. Haugen M, Brantsaeter AL, Trogstad L et al. Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. Epidemiology 2009; 20: 720-726.
124. Powe CE, Seely EW, Rana S et al. First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension 2010; 56: 758-763.
125. Jensen DM, Damm P, Sørensen B et al. Pregnancy outcome and prepregnancy body mass index in 2459 glucose-tolerant Danish women. Am J Obstet Gynecol 2003; 189: 239-244. (Pubitemid 36886556)
126. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol 2004; 103: 219-224.
127. Weiss JL, Malone FD, Emig D, et al. FASTER Research Consortium. Obesity, obstetric complications and cesarean delivery rate: a population-based screening study. Am J Obstet Gynecol 2004; 190: 1091-1097. (Pubitemid 38561531)
128. O'Brien TE, Ray JG & Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003; 14: 368-374. (Pubitemid 40417091)
129. Maggard MA, Yermilov I, Li Z et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008; 300: 2286-2296.
130. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002; 100: 369-377. (Pubitemid 34874806)
131. Gilbert WM, Young AL & Danielsen B. Pregnancy outcomes in women with chronic hypertension: a population-based study. J Reprod Med 2007; 52: 1046-1051. (Pubitemid 350305089)
132. Nakhai-Pour HR, Rey E & Bérard A. Discontinuation of antihypertensive drug use during the first trimester of pregnancy and the risk of preeclampsia and eclampsia among women with chronic hypertension. Am J Obstet Gynecol 2009; 201: 180.e1-180.e8.
133. von Dadelszen P & Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002; 24: 941-945.
134. Rosenn B, Miodovnik M, Combs CA et al. Glycemic thresholds for spontaneous abortion and congenital malformations in insulin-dependent diabetes mellitus. Obstet Gynecol 1994; 84: 515-520. (Pubitemid 24311140)
135. Temple R, Aldridge V, Greenwood R et al. Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population based study. BMJ 2002; 325: 1275-1276. (Pubitemid 35430583)
136. Hanson U & Persson B. Outcome of pregnancies complicated by type 1 insulin-dependent diabetes in Sweden: acute pregnancy complications, neonatal mortality and morbidity. Am J Perinatol 1993; 10: 330-333. (Pubitemid 23208733)
137. Sibai BM, Caritis S, Hauth J et al. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National institute of child health and human development network of maternal-fetal medicine units. Am J Obstet Gynecol 2000; 182: 364-369. (Pubitemid 30127349)
138. Duckitt K & Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565.
139. Bodnar LM, Tang G, Ness RB et al. Periconceptional multivitamin use reduces the risk of preeclampsia. Am J Epidemiol 2006; 164: 470-477. (Pubitemid 44576614)
140. Catov JM, Nohr EA, Bodnar LM et al. Association of periconceptional multivitamin use with reduced risk of preeclampsia among normal-weight women in the Danish National Birth Cohort. Am J Epidemiol 2009; 169: 1304-1311.
141. Lambers MJ, Groeneveld E, Hoozemans DA et al. Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Hum Reprod 2009; 24: 2447-2450.
142. Haapsamo M, Martikainen H, Tinkanen H et al. Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. Hum Reprod 2010; 25: 2972-2977.
143. Zhang J, Klebanoff MA, Levine RJ et al. The puzzling association between smoking and hypertension during pregnancy. Am J Obstet Gynecol 1999; 181: 1407-1413. (Pubitemid 30021885)
144. Hammoud AO, Bujold E, Sorokin Y et al. Smoking in pregnancy revisited: findings from a large population-based study. Am J Obstet Gynecol 2005; 192: 1856-1862.
145. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res 2004; 6: S125-S140. (Pubitemid 38678838)
146. Salihu HM & Wilson RE. Epidemiology of prenatal smoking and perinatal outcomes. Early Hum Dev 2007; 83: 713-720. (Pubitemid 350018713)
147. Cnattingius S, Mills JL, Yuen J et al. The paradoxical effect of smoking in preeclamptic pregnancies: smoking reduces the incidence but increases the rates of perinatal mortality, abruptio placentae, and intrauterine growth restriction. Am J Obstet Gynecol 1997; 177: 156-161. (Pubitemid 27327328)
148. Bestwick JP, Huttly WJ & Wald NJ. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency. J Med Screen 2008; 15: 204-206.
149. Rudnicka AR, Wald NJ, Huttly W et al. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. Prenat Diagn 2002; 22: 893-897. (Pubitemid 35175989)
150. Cleary-Goldman J, Malone FD, Vidaver J, et al. FASTER Consortium. Impact of maternal age on obstetric outcome. Obstet Gynecol 2005; 105: 983-990.
151. Reddy UM, Wapner RJ, Rebar RW et al. Infertility, assisted reproductive technology, and adverse pregnancy outcomes: executive summary of a National Institute of Child Health and Human Development workshop. Obstet Gynecol 2007; 109: 967-977. (Pubitemid 46559087)
152. Steures P, van der Steeg JW, Hompes PG, et al. For the Collaborative Effort on the Clinical Evaluation in Reproductive Medicine. Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial. Lancet 2006; 368: 216-221.
153. Kuohung W, Ginsburg E & Racowsky C. In Rose BD (ed.). Strategies to control the rate of high order multiple gestation. Waltham, MA: UpToDate, 2010.
154. Zhu BP, Rolfs RT, Nangle BE et al. Effect of the interval between
155. Conde-Agudelo A, Rosas-Bermudez A & Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA 2006; 295: 1809-1823.
156. Conde-Agudelo A, Rosas-Bermúdez A & Kafury-Goeta AC. Effects of birth spacing on maternal health: a systematic review. Am J Obstet Gynecol 2007; 196: 297-308. (Pubitemid 46497897)
157. Zhu BP, Grigorescu V, Le T et al. Labor dystocia and its association with interpregnancy interval. Am J Obstet Gynecol 2006; 195: 121-128.
158. CooperWO, Willy ME, Pont SJ et al. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196: 544. e1-544.e5.
159. Toh S, Mitchell AA, Louik C et al. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 2009; 166: 320-328.
160. Nakhai-Pour HR, Broy P & Bérard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010; 182: 1031-1037.
161. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline No. 45. Antenatal and Postnatal Mental Health. Clinical Management and Service Guidance 2007. pp. 27.